Reasons for non-feasibility of therapeutic drug monitoring of oral targeted therapies in oncology – an analysis of the closed cohorts of a multicentre prospective study
Background Therapeutic drug monitoring (TDM) – performing dose adjustments based on measured drug levels and established pharmacokinetic (PK) targets – could optimise treatment with drugs that show large interpatient variability in exposure. We evaluated the feasibility of TDM for multiple oral targ...
Saved in:
| Published in | British journal of cancer Vol. 131; no. 5; pp. 843 - 851 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
Nature Publishing Group UK
01.09.2024
Nature Publishing Group |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Background
Therapeutic drug monitoring (TDM) – performing dose adjustments based on measured drug levels and established pharmacokinetic (PK) targets – could optimise treatment with drugs that show large interpatient variability in exposure. We evaluated the feasibility of TDM for multiple oral targeted therapies. Here we report on drugs for which routine TDM is not feasible.
Methods
We evaluated drug cohorts from the Dutch Pharmacology Oncology Group – TDM study. Based on PK levels taken at pre-specified time points, PK-guided interventions were performed. Feasibility of TDM was evaluated, and based on the success and practicability of TDM, cohorts could be closed.
Results
For 10 out of 24 cohorts TDM was not feasible and inclusion was closed. A high incidence of adverse events resulted in closing the cabozantinib, dabrafenib/trametinib, everolimus, regorafenib and vismodegib cohort. The enzalutamide and erlotinib cohorts were closed because almost all PK levels were above target. Other, non-pharmacological reasons led to closing the palbociclib, olaparib and tamoxifen cohort.
Conclusions
Although TDM could help personalising treatment for many drugs, the above-mentioned reasons can influence its feasibility, usefulness and clinical applicability. Therefore, routine TDM is not advised for cabozantinib, dabrafenib/trametinib, enzalutamide, erlotinib, everolimus, regorafenib and vismodegib. Nonetheless, TDM remains valuable for individual clinical decisions. |
|---|---|
| AbstractList | Abstract Background Therapeutic drug monitoring (TDM) – performing dose adjustments based on measured drug levels and established pharmacokinetic (PK) targets – could optimise treatment with drugs that show large interpatient variability in exposure. We evaluated the feasibility of TDM for multiple oral targeted therapies. Here we report on drugs for which routine TDM is not feasible. Methods We evaluated drug cohorts from the Dutch Pharmacology Oncology Group – TDM study. Based on PK levels taken at pre-specified time points, PK-guided interventions were performed. Feasibility of TDM was evaluated, and based on the success and practicability of TDM, cohorts could be closed. Results For 10 out of 24 cohorts TDM was not feasible and inclusion was closed. A high incidence of adverse events resulted in closing the cabozantinib, dabrafenib/trametinib, everolimus, regorafenib and vismodegib cohort. The enzalutamide and erlotinib cohorts were closed because almost all PK levels were above target. Other, non-pharmacological reasons led to closing the palbociclib, olaparib and tamoxifen cohort. Conclusions Although TDM could help personalising treatment for many drugs, the above-mentioned reasons can influence its feasibility, usefulness and clinical applicability. Therefore, routine TDM is not advised for cabozantinib, dabrafenib/trametinib, enzalutamide, erlotinib, everolimus, regorafenib and vismodegib. Nonetheless, TDM remains valuable for individual clinical decisions. Therapeutic drug monitoring (TDM) - performing dose adjustments based on measured drug levels and established pharmacokinetic (PK) targets - could optimise treatment with drugs that show large interpatient variability in exposure. We evaluated the feasibility of TDM for multiple oral targeted therapies. Here we report on drugs for which routine TDM is not feasible.BACKGROUNDTherapeutic drug monitoring (TDM) - performing dose adjustments based on measured drug levels and established pharmacokinetic (PK) targets - could optimise treatment with drugs that show large interpatient variability in exposure. We evaluated the feasibility of TDM for multiple oral targeted therapies. Here we report on drugs for which routine TDM is not feasible.We evaluated drug cohorts from the Dutch Pharmacology Oncology Group - TDM study. Based on PK levels taken at pre-specified time points, PK-guided interventions were performed. Feasibility of TDM was evaluated, and based on the success and practicability of TDM, cohorts could be closed.METHODSWe evaluated drug cohorts from the Dutch Pharmacology Oncology Group - TDM study. Based on PK levels taken at pre-specified time points, PK-guided interventions were performed. Feasibility of TDM was evaluated, and based on the success and practicability of TDM, cohorts could be closed.For 10 out of 24 cohorts TDM was not feasible and inclusion was closed. A high incidence of adverse events resulted in closing the cabozantinib, dabrafenib/trametinib, everolimus, regorafenib and vismodegib cohort. The enzalutamide and erlotinib cohorts were closed because almost all PK levels were above target. Other, non-pharmacological reasons led to closing the palbociclib, olaparib and tamoxifen cohort.RESULTSFor 10 out of 24 cohorts TDM was not feasible and inclusion was closed. A high incidence of adverse events resulted in closing the cabozantinib, dabrafenib/trametinib, everolimus, regorafenib and vismodegib cohort. The enzalutamide and erlotinib cohorts were closed because almost all PK levels were above target. Other, non-pharmacological reasons led to closing the palbociclib, olaparib and tamoxifen cohort.Although TDM could help personalising treatment for many drugs, the above-mentioned reasons can influence its feasibility, usefulness and clinical applicability. Therefore, routine TDM is not advised for cabozantinib, dabrafenib/trametinib, enzalutamide, erlotinib, everolimus, regorafenib and vismodegib. Nonetheless, TDM remains valuable for individual clinical decisions.CONCLUSIONSAlthough TDM could help personalising treatment for many drugs, the above-mentioned reasons can influence its feasibility, usefulness and clinical applicability. Therefore, routine TDM is not advised for cabozantinib, dabrafenib/trametinib, enzalutamide, erlotinib, everolimus, regorafenib and vismodegib. Nonetheless, TDM remains valuable for individual clinical decisions. Therapeutic drug monitoring (TDM) - performing dose adjustments based on measured drug levels and established pharmacokinetic (PK) targets - could optimise treatment with drugs that show large interpatient variability in exposure. We evaluated the feasibility of TDM for multiple oral targeted therapies. Here we report on drugs for which routine TDM is not feasible. We evaluated drug cohorts from the Dutch Pharmacology Oncology Group - TDM study. Based on PK levels taken at pre-specified time points, PK-guided interventions were performed. Feasibility of TDM was evaluated, and based on the success and practicability of TDM, cohorts could be closed. For 10 out of 24 cohorts TDM was not feasible and inclusion was closed. A high incidence of adverse events resulted in closing the cabozantinib, dabrafenib/trametinib, everolimus, regorafenib and vismodegib cohort. The enzalutamide and erlotinib cohorts were closed because almost all PK levels were above target. Other, non-pharmacological reasons led to closing the palbociclib, olaparib and tamoxifen cohort. Although TDM could help personalising treatment for many drugs, the above-mentioned reasons can influence its feasibility, usefulness and clinical applicability. Therefore, routine TDM is not advised for cabozantinib, dabrafenib/trametinib, enzalutamide, erlotinib, everolimus, regorafenib and vismodegib. Nonetheless, TDM remains valuable for individual clinical decisions. BackgroundTherapeutic drug monitoring (TDM) – performing dose adjustments based on measured drug levels and established pharmacokinetic (PK) targets – could optimise treatment with drugs that show large interpatient variability in exposure. We evaluated the feasibility of TDM for multiple oral targeted therapies. Here we report on drugs for which routine TDM is not feasible.MethodsWe evaluated drug cohorts from the Dutch Pharmacology Oncology Group – TDM study. Based on PK levels taken at pre-specified time points, PK-guided interventions were performed. Feasibility of TDM was evaluated, and based on the success and practicability of TDM, cohorts could be closed.ResultsFor 10 out of 24 cohorts TDM was not feasible and inclusion was closed. A high incidence of adverse events resulted in closing the cabozantinib, dabrafenib/trametinib, everolimus, regorafenib and vismodegib cohort. The enzalutamide and erlotinib cohorts were closed because almost all PK levels were above target. Other, non-pharmacological reasons led to closing the palbociclib, olaparib and tamoxifen cohort.ConclusionsAlthough TDM could help personalising treatment for many drugs, the above-mentioned reasons can influence its feasibility, usefulness and clinical applicability. Therefore, routine TDM is not advised for cabozantinib, dabrafenib/trametinib, enzalutamide, erlotinib, everolimus, regorafenib and vismodegib. Nonetheless, TDM remains valuable for individual clinical decisions. Background Therapeutic drug monitoring (TDM) – performing dose adjustments based on measured drug levels and established pharmacokinetic (PK) targets – could optimise treatment with drugs that show large interpatient variability in exposure. We evaluated the feasibility of TDM for multiple oral targeted therapies. Here we report on drugs for which routine TDM is not feasible. Methods We evaluated drug cohorts from the Dutch Pharmacology Oncology Group – TDM study. Based on PK levels taken at pre-specified time points, PK-guided interventions were performed. Feasibility of TDM was evaluated, and based on the success and practicability of TDM, cohorts could be closed. Results For 10 out of 24 cohorts TDM was not feasible and inclusion was closed. A high incidence of adverse events resulted in closing the cabozantinib, dabrafenib/trametinib, everolimus, regorafenib and vismodegib cohort. The enzalutamide and erlotinib cohorts were closed because almost all PK levels were above target. Other, non-pharmacological reasons led to closing the palbociclib, olaparib and tamoxifen cohort. Conclusions Although TDM could help personalising treatment for many drugs, the above-mentioned reasons can influence its feasibility, usefulness and clinical applicability. Therefore, routine TDM is not advised for cabozantinib, dabrafenib/trametinib, enzalutamide, erlotinib, everolimus, regorafenib and vismodegib. Nonetheless, TDM remains valuable for individual clinical decisions. |
| Author | Westerdijk, Kim Moes, Dirk-Jan A. R. Meertens, Marinda Lubberman, Floor J. E. Touw, Daan J. Reyners, An K. L. Fiebrich-Westra, Helle-Brit Desar, Ingrid M. E. Guchelaar, Niels A. D. van der Kleij, Maud B. A. Groenland, Stefanie L. van Eerden, Ruben A. G. Gelderblom, Hans Huitema, Alwin D. R. Otten, Hans-Martin Giraud, Eline L. Bleckman, Roos F. Imholz, Alex L. T. Vulink, Annelie J. E. van Erp, Nielka P. Koolen, Stijn L. W. Mathijssen, Ron H. J. Steeghs, Neeltje |
| Author_xml | – sequence: 1 givenname: Maud B. A. orcidid: 0009-0008-8492-8039 surname: van der Kleij fullname: van der Kleij, Maud B. A. email: m.vd.kleij@nki.nl organization: Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Department of Medical Oncology, Erasmus MC Cancer Institute – sequence: 2 givenname: Niels A. D. orcidid: 0000-0001-8080-9093 surname: Guchelaar fullname: Guchelaar, Niels A. D. organization: Department of Medical Oncology, Erasmus MC Cancer Institute – sequence: 3 givenname: Marinda surname: Meertens fullname: Meertens, Marinda organization: Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek – sequence: 4 givenname: Kim surname: Westerdijk fullname: Westerdijk, Kim organization: Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Centre – sequence: 5 givenname: Eline L. surname: Giraud fullname: Giraud, Eline L. organization: Department of Pharmacy and Clinical Pharmacology, Research Institute for Medical Innovation, Radboud University Medical Centre – sequence: 6 givenname: Roos F. surname: Bleckman fullname: Bleckman, Roos F. organization: Department of Medical Oncology, University Medical Centre Groningen, University of Groningen – sequence: 7 givenname: Stefanie L. orcidid: 0000-0002-5085-3787 surname: Groenland fullname: Groenland, Stefanie L. organization: Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek – sequence: 8 givenname: Ruben A. G. orcidid: 0000-0001-8937-3425 surname: van Eerden fullname: van Eerden, Ruben A. G. organization: Department of Medical Oncology, Erasmus MC Cancer Institute – sequence: 9 givenname: Alex L. T. surname: Imholz fullname: Imholz, Alex L. T. organization: Department of Medical Oncology, Deventer Hospital – sequence: 10 givenname: Annelie J. E. surname: Vulink fullname: Vulink, Annelie J. E. organization: Department of Medical Oncology, Reinier de Graaf Hospital – sequence: 11 givenname: Hans-Martin surname: Otten fullname: Otten, Hans-Martin organization: Department of Medical Oncology, Meander Medical Centre – sequence: 12 givenname: Helle-Brit surname: Fiebrich-Westra fullname: Fiebrich-Westra, Helle-Brit organization: Department of Medical Oncology, Isala Hospital – sequence: 13 givenname: Floor J. E. surname: Lubberman fullname: Lubberman, Floor J. E. organization: Department of Pharmacy, Gelderse Vallei Hospital – sequence: 14 givenname: Ingrid M. E. surname: Desar fullname: Desar, Ingrid M. E. organization: Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Centre – sequence: 15 givenname: Dirk-Jan A. R. orcidid: 0000-0003-3219-253X surname: Moes fullname: Moes, Dirk-Jan A. R. organization: Department of Clinical Pharmacy & Toxicology, Leiden University Medical Centre – sequence: 16 givenname: Daan J. surname: Touw fullname: Touw, Daan J. organization: Department of Clinical Pharmacy and Pharmacology, University Medical Centre Groningen, University of Groningen – sequence: 17 givenname: Stijn L. W. surname: Koolen fullname: Koolen, Stijn L. W. organization: Department of Medical Oncology, Erasmus MC Cancer Institute, Department of Pharmacy, Erasmus University Medical Centre – sequence: 18 givenname: Hans surname: Gelderblom fullname: Gelderblom, Hans organization: Department of Medical Oncology, Leiden University Medical Centre – sequence: 19 givenname: An K. L. orcidid: 0000-0003-1678-7816 surname: Reyners fullname: Reyners, An K. L. organization: Department of Medical Oncology, University Medical Centre Groningen, University of Groningen – sequence: 20 givenname: Nielka P. surname: van Erp fullname: van Erp, Nielka P. organization: Department of Pharmacy and Clinical Pharmacology, Research Institute for Medical Innovation, Radboud University Medical Centre – sequence: 21 givenname: Ron H. J. orcidid: 0000-0001-5667-5697 surname: Mathijssen fullname: Mathijssen, Ron H. J. organization: Department of Medical Oncology, Erasmus MC Cancer Institute – sequence: 22 givenname: Alwin D. R. surname: Huitema fullname: Huitema, Alwin D. R. organization: Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Department of Clinical Pharmacy, Utrecht University Medical Centre, Department of Pharmacology, Princess Máxima Centre for Paediatric Oncology – sequence: 24 givenname: Neeltje orcidid: 0000-0003-2989-2279 surname: Steeghs fullname: Steeghs, Neeltje organization: Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Department of Medical Oncology, Utrecht University Medical Centre, Utrecht University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38971952$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9UtuK1TAUDTLinBn9AR8k4Isv1VzapHkSGbzBgCD6HNI07cmQJjVJB_rmP_gXfpZfYnrOcbw8CAlhZ6-99srOugBnPngDwGOMnmNE2xepxjVmFSJ12bwVFbkHdrihpMIt4WdghxDiFRIEnYOLlG5KKFDLH4Bz2gqORUN24PtHo1LwCQ4hwsJfDSW2nXU2rzAMMO9NVLNZstWwj8sIp-BtDtH6cUuHqBzMKo4mm_4EtiZB62HwOrgwrvDH129Q-bKUW5NNJ1aoXUilRod9iPlwq-C0uNLI-BwNnGNIs9HZ3hqY8tKvD8H9QblkHp3OS_D5zetPV--q6w9v31-9uq40bViuWKOZ7gnipEaccSQ6xuoyL01p1ypFcUdxzXjbYzYwQQeMOdKKUk6xwQ0j9BK8PPLOSzeZ_iBHOTlHO6m4yqCs_Dvj7V6O4VZiTJkg7cbw7MQQw5fFpCwnm7RxTnkTliRpEVYTwkVdoE__gd6EJZZRbSghRM0YbQqKHFG6DCVFM9ypwUhuXpBHL8jiBXnwgtxUPPnzHXclvz6_AOgRkObtP0383fs_tD8BJh_FMw |
| Cites_doi | 10.1016/S0140-6736(10)60172-9 10.1007/s00280-014-2599-1 10.1097/FTD.0b013e3181b2c8cf 10.1016/j.esmoop.2021.100312 10.1016/j.eururo.2015.01.026 10.1007/s40262-014-0137-2 10.1186/s12885-022-09338-1 10.3389/fonc.2023.1144056 10.1007/s00280-023-04601-z 10.1038/bjc.2014.194 10.1007/s00280-021-04269-3 10.1007/s40262-021-01077-z 10.1158/1078-0432.CCR-20-4555 10.1007/s00228-019-02704-2 10.1007/s11095-023-03497-x 10.1007/s40262-023-01293-9 10.1038/clpt.2011.32 10.1016/j.esmoop.2021.100301 10.1097/FTD.0000000000000767 10.1007/s00280-016-2993-y 10.1158/1078-0432.CCR-15-1470 10.1016/S1470-2045(13)70464-9 10.1056/NEJMp2109826 10.1111/bcp.13327 10.1016/j.ejca.2020.02.012 10.1016/j.ejca.2013.11.022 10.1007/s00280-018-3579-7 10.1007/s40262-022-01167-6 10.1016/j.biopha.2023.114906 10.1016/j.ejca.2020.05.025 10.1097/FTD.0000000000000349 10.1186/s12885-018-5043-9 10.1007/s00280-022-04432-4 10.1016/j.annonc.2022.06.010 10.1097/FTD.0000000000000654 10.1200/JCO.2012.43.5966 10.1200/JCO.2001.19.13.3267 10.1016/j.biopha.2022.113393 10.1007/s11523-016-0435-8 10.1158/1078-0432.CCR-16-1255 10.1007/s00280-022-04452-0 10.1056/NEJMoa0900212 10.1016/j.euo.2024.02.009 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2024 2024. The Author(s). The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2024 2024 |
| Copyright_xml | – notice: The Author(s) 2024 – notice: 2024. The Author(s). – notice: The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2024 2024 |
| CorporateAuthor | Dutch Pharmacology Oncology Group (DPOG) |
| CorporateAuthor_xml | – name: Dutch Pharmacology Oncology Group (DPOG) |
| DBID | C6C CGR CUY CVF ECM EIF NPM AAYXX CITATION 7TO 7U9 H94 K9. NAPCQ 7X8 5PM |
| DOI | 10.1038/s41416-024-02789-2 |
| DatabaseName | SpringerOpen Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE - Academic MEDLINE AIDS and Cancer Research Abstracts |
| Database_xml | – sequence: 1 dbid: C6C name: SpringerOpen url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1532-1827 |
| EndPage | 851 |
| ExternalDocumentID | 10_1038_s41416_024_02789_2 38971952 |
| Genre | Multicenter Study Journal Article |
| GrantInformation_xml | – fundername: Pfizer (Pfizer Inc.) grantid: Unrestricted grant, no grant number funderid: https://doi.org/10.13039/100004319 – fundername: Novartis grantid: Unrestricted grant, no grant number funderid: https://doi.org/10.13039/100004336 – fundername: Ipsen Fund grantid: Unrestricted grant, no grant number funderid: https://doi.org/10.13039/501100001254 – fundername: Roche (F. Hoffmann-La Roche Ltd) grantid: Unrestricted grant, no grant number funderid: https://doi.org/10.13039/100004337 – fundername: GlaxoSmithKline (GlaxoSmithKline plc.) grantid: Unrestricted grant, no grant number funderid: https://doi.org/10.13039/100004330 – fundername: Novartis grantid: Unrestricted grant, no grant number – fundername: GlaxoSmithKline (GlaxoSmithKline plc.) grantid: Unrestricted grant, no grant number – fundername: Pfizer (Pfizer Inc.) grantid: Unrestricted grant, no grant number – fundername: Roche (F. Hoffmann-La Roche Ltd) grantid: Unrestricted grant, no grant number – fundername: Ipsen Fund grantid: Unrestricted grant, no grant number |
| GroupedDBID | --- 0R~ 23N 36B 39C 4.4 406 53G 5GY 5RE 6J9 70F 7RV AACDK AANZL AASML AATNV AAWBL AAWTL AAZLF ABAKF ABLJU ABOCM ABZZP ACAOD ACGFO ACGFS ACKTT ACPRK ACRQY ACZOJ ADBBV ADFRT ADHDB AEFQL AEJRE AEMSY AENEX AEVLU AEXYK AFBBN AFRAH AFSHS AGAYW AGEZK AGHAI AGQEE AHMBA AHSBF AIGIU AILAN AJRNO ALFFA ALMA_UNASSIGNED_HOLDINGS AMYLF AOIJS ASPBG AVWKF AXYYD AZFZN BAWUL BENPR BHPHI BKKNO C6C CS3 DNIVK DPUIP DU5 E3Z EAP EBLON EBS EE. EIOEI EMB F5P FDQFY FEDTE FERAY FIGPU FRJ FSGXE GX1 HCIFZ HVGLF HZ~ IH2 IWAJR JSO JZLTJ KQ8 NQJWS O9- OK1 P2P RNT RNTTT RPM SNX SNYQT SOHCF SRMVM SWTZT TAOOD TBHMF TDRGL TR2 W2D WH7 ~02 -Q- .55 .GJ 3V. 7X7 88E 8AO 8C1 8FI 8FJ 8R4 8R5 8WZ A6W AAYZH ABAWZ ABDBF ABUWG AFKRA AI. AN0 B0M BBNVY BKEYQ BNQBC BPHCQ BVXVI CAG CCPQU CGR COF CUY CVF DIK EAD EAS EBC EBD ECM EIF EJD EMK EMOBN EPL ESX EX3 FIZPM FYUFA HMCUK HYE J5H M1P M41 M7P NAO NAPCQ NPM PQQKQ PROAC PSQYO Q2X SV3 TUS UDS UKHRP VH1 WOW X7M Y6R ZGI ~8M AAYXX CITATION 7TO 7U9 H94 K9. 7X8 5PM |
| ID | FETCH-LOGICAL-c356t-65c6cd20724076709b664103c33b8aa31b314678d16f693f1170ca33731e15623 |
| IEDL.DBID | C6C |
| ISSN | 0007-0920 1532-1827 |
| IngestDate | Tue Sep 17 21:28:02 EDT 2024 Sat Oct 26 04:09:48 EDT 2024 Thu Oct 10 21:54:42 EDT 2024 Thu Sep 26 20:32:47 EDT 2024 Tue Oct 29 09:18:20 EDT 2024 Fri Oct 11 20:37:40 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Language | English |
| License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c356t-65c6cd20724076709b664103c33b8aa31b314678d16f693f1170ca33731e15623 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-5085-3787 0009-0008-8492-8039 0000-0001-8937-3425 0000-0001-8080-9093 0000-0003-1678-7816 0000-0003-3219-253X 0000-0001-5667-5697 0000-0003-2989-2279 |
| OpenAccessLink | https://doi.org/10.1038/s41416-024-02789-2 |
| PMID | 38971952 |
| PQID | 3099946635 |
| PQPubID | 41855 |
| PageCount | 9 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_11369282 proquest_miscellaneous_3076422794 proquest_journals_3099946635 crossref_primary_10_1038_s41416_024_02789_2 pubmed_primary_38971952 springer_journals_10_1038_s41416_024_02789_2 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-Sep |
| PublicationDateYYYYMMDD | 2024-09-01 |
| PublicationDate_xml | – month: 09 year: 2024 text: 2024-Sep |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | British journal of cancer |
| PublicationTitleAbbrev | Br J Cancer |
| PublicationTitleAlternate | Br J Cancer |
| PublicationYear | 2024 |
| Publisher | Nature Publishing Group UK Nature Publishing Group |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group |
| References | Lankheet, Desar, Mulder, Burger, Kweekel, van Herpen (CR13) 2017; 83 Groenland, van Eerden, Verheijen, Koolen, Moes, Desar (CR18) 2019; 41 Lin, van der Meer, Steeghs, Beijnen, Huitema (CR38) 2024; 93 Guchelaar, van Eerden, Groenland, van Doorn, Desar, Eskens (CR17) 2022; 153 Rini, Melichar, Ueda, Grünwald, Fishman, Arranz (CR33) 2013; 14 Lacy, Nielsen, Yang, Miles, Nguyen, Hutmacher (CR23) 2018; 81 Boerrigter, Havenith, van Erp, Schnog (CR36) 2021; 88 Verheijen, Bins, Mathijssen, Lolkema, van Doorn, Schellens (CR14) 2016; 22 Cerbone, Combarel, Geraud, Auclin, Foulon, Alves Costa Silva (CR30) 2021; 6 Braal, Jager, Hoop, Westenberg, Lommen, de Bruijn (CR9) 2022; 61 CR37 Bruin, Sonke, Beijnen, Huitema (CR22) 2022; 61 Mateo, Moreno, Gupta, Kaye, Dean, Middleton (CR27) 2016; 11 Wang, Chia, Nedelman, Schran, Mahon, Molimard (CR21) 2009; 31 Fiala, Hosek, Pesek, Finek, Racek, Stehlik (CR25) 2017; 37 van der Kleij, Guchelaar, Mathijssen, Versluis, Huitema, Koolen (CR6) 2023; 62 CR32 Higano, Beer, Taplin, Efstathiou, Hirmand, Forer (CR34) 2015; 68 Roncato, Peruzzi, Gerratana, Posocco, Nuzzo, Montico (CR39) 2023; 164 Yu, Steeghs, Nijenhuis, Schellens, Beijnen, Huitema (CR1) 2014; 53 IJzerman, Groenland, Koenen, Kerst, van der Graaf, Rosing (CR11) 2020; 136 Kim, Kefford, Pavlick, Infante, Ribas, Sosman (CR42) 2013; 31 Ravaud, Urva, Grosch, Cheung, Anak, Sellami (CR43) 2014; 50 Janssen, Dorlo, Beijnen, Huitema (CR20) 2020; 42 Kenmotsu, Imamura, Kawamura, Oyakawa, Omori, Nakashima (CR26) 2022; 90 Madlensky, Natarajan, Tchu, Pu, Mortimer, Flatt (CR47) 2011; 89 Groenland, Mathijssen, Beijnen, Huitema, Steeghs (CR2) 2019; 75 Groenland, van Nuland, Bergman, de Feijter, Dezentje, Rosing (CR15) 2020; 130 Groenland, Katz, Huitema, Steeghs (CR40) 2018; 18 Fong, Boss, Yap, Tutt, Wu, Mergui-Roelvink (CR44) 2009; 361 Murphy, Halford, Symeonides (CR5) 2023; 13 Herbrink, de Vries, Rosing, Huitema, Nuijen, Schellens (CR19) 2016; 38 Mohmaed Ali, Bruin, Dezentjé, Beijnen, Steeghs, Huitema (CR28) 2023; 40 Scher, Beer, Higano, Anand, Taplin, Efstathiou (CR35) 2010; 375 CR48 CR46 CR45 Gandhi, Joshi, Mehta, Gurjar, Rane, Sharma (CR7) 2022; 89 Hidalgo, Siu, Nemunaitis, Rizzo, Hammond, Takimoto (CR24) 2001; 19 Shah, Rahman, Theoret, Pazdur (CR4) 2021; 385 Groenland, van Eerden, Westerdijk, Meertens, Koolen, Moes (CR16) 2022; 33 Groenland, Verheijen, Joerger, Mathijssen, Sparreboom, Beijnen (CR31) 2021; 27 Maliepaard, Carree, van Bussel (CR3) 2021; 6 Lankheet, Kloth, Gadellaa-van Hooijdonk, Cirkel, Mathijssen, Lolkema (CR12) 2014; 110 Ouellet, Kassir, Chiu, Mouksassi, Leonowens, Cox (CR41) 2016; 77 Gotta, Widmer, Decosterd, Chalandon, Heim, Gregor (CR8) 2014; 74 Krens, van Erp, Groenland, Moes, Mulder, Desar (CR29) 2022; 22 Fox, Balleine, Lee, Gao, Balakrishnar, Menzies (CR10) 2016; 22 J Mateo (2789_CR27) 2016; 11 HI Scher (2789_CR35) 2010; 375 SL Groenland (2789_CR15) 2020; 130 MAC Bruin (2789_CR22) 2022; 61 M Herbrink (2789_CR19) 2016; 38 L Lin (2789_CR38) 2024; 93 A Ravaud (2789_CR43) 2014; 50 R Roncato (2789_CR39) 2023; 164 V Gotta (2789_CR8) 2014; 74 CL Braal (2789_CR9) 2022; 61 NAG Lankheet (2789_CR13) 2017; 83 JM Janssen (2789_CR20) 2020; 42 O Fiala (2789_CR25) 2017; 37 PC Fong (2789_CR44) 2009; 361 NA Lankheet (2789_CR12) 2014; 110 H Yu (2789_CR1) 2014; 53 2789_CR37 KB Kim (2789_CR42) 2013; 31 SL Groenland (2789_CR2) 2019; 75 H Kenmotsu (2789_CR26) 2022; 90 L Cerbone (2789_CR30) 2021; 6 SL Groenland (2789_CR40) 2018; 18 D Ouellet (2789_CR41) 2016; 77 NAD Guchelaar (2789_CR17) 2022; 153 2789_CR32 Y Wang (2789_CR21) 2009; 31 KA Gandhi (2789_CR7) 2022; 89 R Murphy (2789_CR5) 2023; 13 S Lacy (2789_CR23) 2018; 81 L Madlensky (2789_CR47) 2011; 89 RB Verheijen (2789_CR14) 2016; 22 P Fox (2789_CR10) 2016; 22 MI Mohmaed Ali (2789_CR28) 2023; 40 BI Rini (2789_CR33) 2013; 14 M Hidalgo (2789_CR24) 2001; 19 M Maliepaard (2789_CR3) 2021; 6 E Boerrigter (2789_CR36) 2021; 88 2789_CR45 CS Higano (2789_CR34) 2015; 68 2789_CR46 MBA van der Kleij (2789_CR6) 2023; 62 2789_CR48 SD Krens (2789_CR29) 2022; 22 SL Groenland (2789_CR16) 2022; 33 SL Groenland (2789_CR18) 2019; 41 M Shah (2789_CR4) 2021; 385 NS IJzerman (2789_CR11) 2020; 136 SL Groenland (2789_CR31) 2021; 27 |
| References_xml | – volume: 375 start-page: 1437 year: 2010 end-page: 46 ident: CR35 article-title: Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study publication-title: Lancet doi: 10.1016/S0140-6736(10)60172-9 contributor: fullname: Efstathiou – ident: CR45 – volume: 74 start-page: 1307 year: 2014 end-page: 19 ident: CR8 article-title: Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial publication-title: Cancer Chemother Pharm doi: 10.1007/s00280-014-2599-1 contributor: fullname: Gregor – volume: 31 start-page: 579 year: 2009 end-page: 84 ident: CR21 article-title: A therapeutic drug monitoring algorithm for refining the imatinib trough level obtained at different sampling times publication-title: Ther Drug Monit doi: 10.1097/FTD.0b013e3181b2c8cf contributor: fullname: Molimard – volume: 6 start-page: 100312 year: 2021 ident: CR30 article-title: Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study publication-title: ESMO Open doi: 10.1016/j.esmoop.2021.100312 contributor: fullname: Alves Costa Silva – volume: 68 start-page: 795 year: 2015 end-page: 801 ident: CR34 article-title: Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer publication-title: Eur Urol doi: 10.1016/j.eururo.2015.01.026 contributor: fullname: Forer – volume: 53 start-page: 305 year: 2014 end-page: 25 ident: CR1 article-title: Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets publication-title: Clin Pharmacokinet doi: 10.1007/s40262-014-0137-2 contributor: fullname: Huitema – volume: 37 start-page: 6469 year: 2017 end-page: 76 ident: CR25 article-title: Serum Concentration of Erlotinib and its Correlation with Outcome and Toxicity in Patients with Advanced-stage NSCLC publication-title: Anticancer Res contributor: fullname: Stehlik – ident: CR37 – volume: 22 year: 2022 ident: CR29 article-title: Exposure–response analyses of cabozantinib in patients with metastatic renal cell cancer publication-title: BMC Cancer doi: 10.1186/s12885-022-09338-1 contributor: fullname: Desar – volume: 13 start-page: 1144056 year: 2023 ident: CR5 article-title: Project Optimus, an FDA initiative: Considerations for cancer drug development internationally, from an academic perspective publication-title: Front Oncol doi: 10.3389/fonc.2023.1144056 contributor: fullname: Symeonides – volume: 93 start-page: 129 year: 2024 end-page: 36 ident: CR38 article-title: Are novel oral oncolytics underdosed in obese patients? publication-title: Cancer Chemother Pharm doi: 10.1007/s00280-023-04601-z contributor: fullname: Huitema – volume: 110 start-page: 2441 year: 2014 end-page: 9 ident: CR12 article-title: Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours publication-title: Br J Cancer doi: 10.1038/bjc.2014.194 contributor: fullname: Lolkema – volume: 88 start-page: 165 year: 2021 end-page: 8 ident: CR36 article-title: Deep and ongoing response of castrate-resistant prostate cancer on very low-dose enzalutamide in an elderly chemotherapy-naïve patient: a case report publication-title: Cancer Chemother Pharm doi: 10.1007/s00280-021-04269-3 contributor: fullname: Schnog – volume: 61 start-page: 527 year: 2022 end-page: 37 ident: CR9 article-title: Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer publication-title: Clin Pharmacokinet doi: 10.1007/s40262-021-01077-z contributor: fullname: de Bruijn – volume: 27 start-page: 6644 year: 2021 end-page: 52 ident: CR31 article-title: Precision Dosing of Targeted Therapies Is Ready for Prime Time publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-20-4555 contributor: fullname: Beijnen – volume: 75 start-page: 1309 year: 2019 end-page: 18 ident: CR2 article-title: Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine publication-title: Eur J Clin Pharm doi: 10.1007/s00228-019-02704-2 contributor: fullname: Steeghs – volume: 40 start-page: 1239 year: 2023 end-page: 47 ident: CR28 article-title: Exposure-Response Analyses of Olaparib in Real-Life Patients with Ovarian Cancer publication-title: Pharm Res doi: 10.1007/s11095-023-03497-x contributor: fullname: Huitema – volume: 62 start-page: 1333 year: 2023 end-page: 64 ident: CR6 article-title: Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology publication-title: Clin Pharmacokinet doi: 10.1007/s40262-023-01293-9 contributor: fullname: Koolen – volume: 89 start-page: 718 year: 2011 end-page: 25 ident: CR47 article-title: Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes publication-title: Clin Pharm Ther doi: 10.1038/clpt.2011.32 contributor: fullname: Flatt – volume: 6 start-page: 100301 year: 2021 ident: CR3 article-title: Dose selection and tolerability of anticancer agents evaluated by the European Medicines Agency in the period 2015-2020 publication-title: ESMO Open doi: 10.1016/j.esmoop.2021.100301 contributor: fullname: van Bussel – volume: 42 start-page: 532 year: 2020 end-page: 9 ident: CR20 article-title: Evaluation of Extrapolation Methods to Predict Trough Concentrations to Guide Therapeutic Drug Monitoring of Oral Anticancer Drugs publication-title: Ther Drug Monit doi: 10.1097/FTD.0000000000000767 contributor: fullname: Huitema – volume: 77 start-page: 807 year: 2016 end-page: 17 ident: CR41 article-title: Population pharmacokinetics and exposure-response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma publication-title: Cancer Chemother Pharm doi: 10.1007/s00280-016-2993-y contributor: fullname: Cox – volume: 22 start-page: 3164 year: 2016 end-page: 71 ident: CR10 article-title: Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring-The TADE Study publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-15-1470 contributor: fullname: Menzies – ident: CR46 – volume: 14 start-page: 1233 year: 2013 end-page: 42 ident: CR33 article-title: Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(13)70464-9 contributor: fullname: Arranz – ident: CR48 – volume: 385 start-page: 1445 year: 2021 end-page: 7 ident: CR4 article-title: The Drug-Dosing Conundrum in Oncology - When Less Is More publication-title: N. Engl J Med doi: 10.1056/NEJMp2109826 contributor: fullname: Pazdur – volume: 83 start-page: 2195 year: 2017 end-page: 204 ident: CR13 article-title: Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib publication-title: Br J Clin Pharm doi: 10.1111/bcp.13327 contributor: fullname: van Herpen – volume: 130 start-page: 32 year: 2020 end-page: 38 ident: CR15 article-title: Concomitant intake of abiraterone acetate and food to increase pharmacokinetic exposure: real life data from a therapeutic drug monitoring programme publication-title: Eur J Cancer doi: 10.1016/j.ejca.2020.02.012 contributor: fullname: Rosing – volume: 50 start-page: 486 year: 2014 end-page: 95 ident: CR43 article-title: Relationship between everolimus exposure and safety and efficacy: meta-analysis of clinical trials in oncology publication-title: Eur J Cancer doi: 10.1016/j.ejca.2013.11.022 contributor: fullname: Sellami – volume: 81 start-page: 1061 year: 2018 end-page: 70 ident: CR23 article-title: Population exposure-response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma publication-title: Cancer Chemother Pharm doi: 10.1007/s00280-018-3579-7 contributor: fullname: Hutmacher – volume: 61 start-page: 1649 year: 2022 end-page: 75 ident: CR22 article-title: Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology publication-title: Clin Pharmacokinet doi: 10.1007/s40262-022-01167-6 contributor: fullname: Huitema – volume: 164 year: 2023 ident: CR39 article-title: Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure publication-title: Biomed Pharmacother doi: 10.1016/j.biopha.2023.114906 contributor: fullname: Montico – volume: 136 start-page: 140 year: 2020 end-page: 8 ident: CR11 article-title: Therapeutic drug monitoring of imatinib in patients with gastrointestinal stromal tumours - Results from daily clinical practice publication-title: Eur J Cancer doi: 10.1016/j.ejca.2020.05.025 contributor: fullname: Rosing – volume: 38 start-page: 649 year: 2016 end-page: 56 ident: CR19 article-title: Quantification of 11 Therapeutic Kinase Inhibitors in Human Plasma for Therapeutic Drug Monitoring Using Liquid Chromatography Coupled With Tandem Mass Spectrometry publication-title: Ther Drug Monit doi: 10.1097/FTD.0000000000000349 contributor: fullname: Schellens – volume: 18 year: 2018 ident: CR40 article-title: Harnessing soft tissue sarcoma with low-dose pazopanib - a matter of blood levels publication-title: BMC Cancer doi: 10.1186/s12885-018-5043-9 contributor: fullname: Steeghs – volume: 89 start-page: 751 year: 2022 end-page: 9 ident: CR7 article-title: Feasibility of therapeutic drug monitoring of sunitinib and its implications on response and toxicity in patients with metastatic renal cell cancer publication-title: Cancer Chemother Pharm doi: 10.1007/s00280-022-04432-4 contributor: fullname: Sharma – ident: CR32 – volume: 33 start-page: 1071 year: 2022 end-page: 82 ident: CR16 article-title: Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study publication-title: Ann Oncol doi: 10.1016/j.annonc.2022.06.010 contributor: fullname: Moes – volume: 41 start-page: 561 year: 2019 end-page: 7 ident: CR18 article-title: Therapeutic Drug Monitoring of Oral Anticancer Drugs: The Dutch Pharmacology Oncology Group-Therapeutic Drug Monitoring Protocol for a Prospective Study publication-title: Ther Drug Monit doi: 10.1097/FTD.0000000000000654 contributor: fullname: Desar – volume: 31 start-page: 482 year: 2013 end-page: 9 ident: CR42 article-title: Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor publication-title: J Clin Oncol doi: 10.1200/JCO.2012.43.5966 contributor: fullname: Sosman – volume: 19 start-page: 3267 year: 2001 end-page: 79 ident: CR24 article-title: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies publication-title: J Clin Oncol doi: 10.1200/JCO.2001.19.13.3267 contributor: fullname: Takimoto – volume: 153 year: 2022 ident: CR17 article-title: Feasibility of therapeutic drug monitoring of sorafenib in patients with liver or thyroid cancer publication-title: Biomed Pharmacother doi: 10.1016/j.biopha.2022.113393 contributor: fullname: Eskens – volume: 11 start-page: 401 year: 2016 end-page: 15 ident: CR27 article-title: An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib publication-title: Target Oncol doi: 10.1007/s11523-016-0435-8 contributor: fullname: Middleton – volume: 22 start-page: 5738 year: 2016 end-page: 46 ident: CR14 article-title: Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-16-1255 contributor: fullname: Schellens – volume: 90 start-page: 115 year: 2022 end-page: 23 ident: CR26 article-title: Prospective evaluation of the relationship between response and exposure of total and unbound erlotinib in non-small cell lung cancer patients publication-title: Cancer Chemother Pharm doi: 10.1007/s00280-022-04452-0 contributor: fullname: Nakashima – volume: 361 start-page: 123 year: 2009 end-page: 34 ident: CR44 article-title: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers publication-title: N. Engl J Med doi: 10.1056/NEJMoa0900212 contributor: fullname: Mergui-Roelvink – volume: 22 year: 2022 ident: 2789_CR29 publication-title: BMC Cancer doi: 10.1186/s12885-022-09338-1 contributor: fullname: SD Krens – volume: 18 year: 2018 ident: 2789_CR40 publication-title: BMC Cancer doi: 10.1186/s12885-018-5043-9 contributor: fullname: SL Groenland – volume: 27 start-page: 6644 year: 2021 ident: 2789_CR31 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-20-4555 contributor: fullname: SL Groenland – volume: 22 start-page: 5738 year: 2016 ident: 2789_CR14 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-16-1255 contributor: fullname: RB Verheijen – volume: 375 start-page: 1437 year: 2010 ident: 2789_CR35 publication-title: Lancet doi: 10.1016/S0140-6736(10)60172-9 contributor: fullname: HI Scher – volume: 88 start-page: 165 year: 2021 ident: 2789_CR36 publication-title: Cancer Chemother Pharm doi: 10.1007/s00280-021-04269-3 contributor: fullname: E Boerrigter – volume: 31 start-page: 579 year: 2009 ident: 2789_CR21 publication-title: Ther Drug Monit doi: 10.1097/FTD.0b013e3181b2c8cf contributor: fullname: Y Wang – volume: 74 start-page: 1307 year: 2014 ident: 2789_CR8 publication-title: Cancer Chemother Pharm doi: 10.1007/s00280-014-2599-1 contributor: fullname: V Gotta – volume: 6 start-page: 100301 year: 2021 ident: 2789_CR3 publication-title: ESMO Open doi: 10.1016/j.esmoop.2021.100301 contributor: fullname: M Maliepaard – volume: 68 start-page: 795 year: 2015 ident: 2789_CR34 publication-title: Eur Urol doi: 10.1016/j.eururo.2015.01.026 contributor: fullname: CS Higano – volume: 130 start-page: 32 year: 2020 ident: 2789_CR15 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2020.02.012 contributor: fullname: SL Groenland – volume: 153 year: 2022 ident: 2789_CR17 publication-title: Biomed Pharmacother doi: 10.1016/j.biopha.2022.113393 contributor: fullname: NAD Guchelaar – volume: 90 start-page: 115 year: 2022 ident: 2789_CR26 publication-title: Cancer Chemother Pharm doi: 10.1007/s00280-022-04452-0 contributor: fullname: H Kenmotsu – volume: 6 start-page: 100312 year: 2021 ident: 2789_CR30 publication-title: ESMO Open doi: 10.1016/j.esmoop.2021.100312 contributor: fullname: L Cerbone – volume: 22 start-page: 3164 year: 2016 ident: 2789_CR10 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-15-1470 contributor: fullname: P Fox – ident: 2789_CR45 – volume: 37 start-page: 6469 year: 2017 ident: 2789_CR25 publication-title: Anticancer Res contributor: fullname: O Fiala – volume: 61 start-page: 1649 year: 2022 ident: 2789_CR22 publication-title: Clin Pharmacokinet doi: 10.1007/s40262-022-01167-6 contributor: fullname: MAC Bruin – volume: 89 start-page: 751 year: 2022 ident: 2789_CR7 publication-title: Cancer Chemother Pharm doi: 10.1007/s00280-022-04432-4 contributor: fullname: KA Gandhi – ident: 2789_CR37 doi: 10.1016/j.euo.2024.02.009 – volume: 41 start-page: 561 year: 2019 ident: 2789_CR18 publication-title: Ther Drug Monit doi: 10.1097/FTD.0000000000000654 contributor: fullname: SL Groenland – volume: 13 start-page: 1144056 year: 2023 ident: 2789_CR5 publication-title: Front Oncol doi: 10.3389/fonc.2023.1144056 contributor: fullname: R Murphy – ident: 2789_CR32 – volume: 62 start-page: 1333 year: 2023 ident: 2789_CR6 publication-title: Clin Pharmacokinet doi: 10.1007/s40262-023-01293-9 contributor: fullname: MBA van der Kleij – volume: 19 start-page: 3267 year: 2001 ident: 2789_CR24 publication-title: J Clin Oncol doi: 10.1200/JCO.2001.19.13.3267 contributor: fullname: M Hidalgo – volume: 33 start-page: 1071 year: 2022 ident: 2789_CR16 publication-title: Ann Oncol doi: 10.1016/j.annonc.2022.06.010 contributor: fullname: SL Groenland – volume: 81 start-page: 1061 year: 2018 ident: 2789_CR23 publication-title: Cancer Chemother Pharm doi: 10.1007/s00280-018-3579-7 contributor: fullname: S Lacy – volume: 110 start-page: 2441 year: 2014 ident: 2789_CR12 publication-title: Br J Cancer doi: 10.1038/bjc.2014.194 contributor: fullname: NA Lankheet – volume: 75 start-page: 1309 year: 2019 ident: 2789_CR2 publication-title: Eur J Clin Pharm doi: 10.1007/s00228-019-02704-2 contributor: fullname: SL Groenland – volume: 136 start-page: 140 year: 2020 ident: 2789_CR11 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2020.05.025 contributor: fullname: NS IJzerman – volume: 83 start-page: 2195 year: 2017 ident: 2789_CR13 publication-title: Br J Clin Pharm doi: 10.1111/bcp.13327 contributor: fullname: NAG Lankheet – volume: 11 start-page: 401 year: 2016 ident: 2789_CR27 publication-title: Target Oncol doi: 10.1007/s11523-016-0435-8 contributor: fullname: J Mateo – volume: 53 start-page: 305 year: 2014 ident: 2789_CR1 publication-title: Clin Pharmacokinet doi: 10.1007/s40262-014-0137-2 contributor: fullname: H Yu – volume: 40 start-page: 1239 year: 2023 ident: 2789_CR28 publication-title: Pharm Res doi: 10.1007/s11095-023-03497-x contributor: fullname: MI Mohmaed Ali – volume: 164 year: 2023 ident: 2789_CR39 publication-title: Biomed Pharmacother doi: 10.1016/j.biopha.2023.114906 contributor: fullname: R Roncato – ident: 2789_CR46 – volume: 61 start-page: 527 year: 2022 ident: 2789_CR9 publication-title: Clin Pharmacokinet doi: 10.1007/s40262-021-01077-z contributor: fullname: CL Braal – volume: 93 start-page: 129 year: 2024 ident: 2789_CR38 publication-title: Cancer Chemother Pharm doi: 10.1007/s00280-023-04601-z contributor: fullname: L Lin – volume: 77 start-page: 807 year: 2016 ident: 2789_CR41 publication-title: Cancer Chemother Pharm doi: 10.1007/s00280-016-2993-y contributor: fullname: D Ouellet – ident: 2789_CR48 – volume: 31 start-page: 482 year: 2013 ident: 2789_CR42 publication-title: J Clin Oncol doi: 10.1200/JCO.2012.43.5966 contributor: fullname: KB Kim – volume: 50 start-page: 486 year: 2014 ident: 2789_CR43 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2013.11.022 contributor: fullname: A Ravaud – volume: 385 start-page: 1445 year: 2021 ident: 2789_CR4 publication-title: N. Engl J Med doi: 10.1056/NEJMp2109826 contributor: fullname: M Shah – volume: 361 start-page: 123 year: 2009 ident: 2789_CR44 publication-title: N. Engl J Med doi: 10.1056/NEJMoa0900212 contributor: fullname: PC Fong – volume: 42 start-page: 532 year: 2020 ident: 2789_CR20 publication-title: Ther Drug Monit doi: 10.1097/FTD.0000000000000767 contributor: fullname: JM Janssen – volume: 89 start-page: 718 year: 2011 ident: 2789_CR47 publication-title: Clin Pharm Ther doi: 10.1038/clpt.2011.32 contributor: fullname: L Madlensky – volume: 38 start-page: 649 year: 2016 ident: 2789_CR19 publication-title: Ther Drug Monit doi: 10.1097/FTD.0000000000000349 contributor: fullname: M Herbrink – volume: 14 start-page: 1233 year: 2013 ident: 2789_CR33 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(13)70464-9 contributor: fullname: BI Rini |
| SSID | ssj0009087 |
| Score | 2.502726 |
| Snippet | Background
Therapeutic drug monitoring (TDM) – performing dose adjustments based on measured drug levels and established pharmacokinetic (PK) targets – could... Therapeutic drug monitoring (TDM) - performing dose adjustments based on measured drug levels and established pharmacokinetic (PK) targets - could optimise... Abstract Background Therapeutic drug monitoring (TDM) – performing dose adjustments based on measured drug levels and established pharmacokinetic (PK) targets... BackgroundTherapeutic drug monitoring (TDM) – performing dose adjustments based on measured drug levels and established pharmacokinetic (PK) targets – could... |
| SourceID | pubmedcentral proquest crossref pubmed springer |
| SourceType | Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 843 |
| SubjectTerms | 692/4028/67/1059 692/4028/67/1059/602 Administration, Oral Anilides - administration & dosage Anilides - pharmacokinetics Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacokinetics Benzamides Biomedical and Life Sciences Biomedicine Cancer Research Drug development Drug Monitoring - methods Drug Resistance Epidemiology Everolimus - administration & dosage Everolimus - pharmacokinetics Feasibility Studies Female Humans Imidazoles - administration & dosage Imidazoles - pharmacokinetics Male Molecular Medicine Molecular Targeted Therapy Neoplasms - drug therapy Nitriles - administration & dosage Nitriles - pharmacokinetics Oncology Oximes - administration & dosage Oximes - pharmacokinetics Pharmacokinetics Phenylthiohydantoin - administration & dosage Phenylthiohydantoin - analogs & derivatives Phenylthiohydantoin - pharmacokinetics Phenylurea Compounds Piperazines Prospective Studies Pyridines - administration & dosage Pyridines - pharmacokinetics Pyridones Pyrimidinones Therapeutic drug monitoring |
| Title | Reasons for non-feasibility of therapeutic drug monitoring of oral targeted therapies in oncology – an analysis of the closed cohorts of a multicentre prospective study |
| URI | https://link.springer.com/article/10.1038/s41416-024-02789-2 https://www.ncbi.nlm.nih.gov/pubmed/38971952 https://www.proquest.com/docview/3099946635 https://www.proquest.com/docview/3076422794 https://pubmed.ncbi.nlm.nih.gov/PMC11369282 |
| Volume | 131 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3NbtQwEB5BKyEuiH9SSjVI3CAiiX8SH9sVqwqpPSAq9RbZjg2VIIv259Ab78Bb9LF4Emac7JalcEDKJbFjxxk7_iYz8w3AK-mVtT42edBsZvTO507GIpeqM9bIGITj2OGTU318Jt-fq_ORJodjYbbs96J5u5AlQYacdhK2NrJHzm3Y5T2Y0zRM9OSaYLdoBn5M_vVmqmIMkPl7G9ub0A1kedNB8g8radp8pvfh3oga8XAQ8wO4FfqHcOdktIs_gqsPwRJwXiBBUCSFPo90Pvi9XuIs4m9RVtjNV5_wa1rK3BkXc5Q-Dj7hoRsrkwaNFz3O-kRrfYk_v_9A29MxkJiMraL_MlvQPZxnd75MVy0mJ8U0qIA06nUwJyYq28dwNn33cXKcj1kYci-UXuZaee27qqhZ92O2N6e1pPfqhXCNtaJ0gr-2TVfqqI2InMrGWyFqUYaS0dUT2KGBh2eAIfHfRVW4ppK1s0ZZGVU0pqu8jl5n8HotlvbbQLbRJiO5aNpBiC0JsU1CbKsM9teSa8eFt2gFI17JMCqDl5tiWjJsB7F9mK24Tk1aV0VfogyeDoLedEf4rS6NosabrSmwqcB03Nsl_cXnRMvN2XEMabAZvFnPluvn-vcw9v6v-nO4W6WZzG5u-7CznK_CC8JFS3cAu4fTo6PTg7QwfgHnVgnK |
| link.rule.ids | 230,315,783,787,888,27938,27939,41134,42203,51590 |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3NbtQwEB5BkYAL4p9AASNxg4jEf4mPqKJaoNsDaqXeLNuxoRJk0f4ceuMdeAseiydhxsluWQoHpFwSO3YmY8ffZGY-AzyXQTkXUltGTW7G4EPpZapKqTrjjExReModnh7qybF8d6JORpocyoXZ8t-L9tVC1ggZSlxJyNtIETmX4YrkvMqOWb13TrBbtQM_Jv16M7waE2T-3sb2InQBWV4MkPzDS5oXn_2bcGNEjez1oOZbcCn2t-HqdPSL34EfH6JD4LxgCEEZGvRlwvMh7vWMzRL7LcuKdfPVR_YlT2XqjIopS58NMeGxGyujBc1OezbrM631Gfv57TtzPR4DicnYKgufZwu8h_bZnS_zVcdykGIWKjKUep3MyTKV7V043n9ztDcpx10YyiCUXpZaBR06XjVk-xHbm9da4nsNQvjWOVF7QV_btqt10kYk2somOCEaUcea0NU92EHB4wNgMfPfJVX5lsvGO6OcTCoZ0_GgU9AFvFirxX4dyDZsdpKL1g5KtKhEm5VoeQG7a83ZceItrCDEKwlGFfBsU4xThvwgro-zFdVp0Ori-CUq4P6g6E13iN-a2ihsvN0aApsKRMe9XdKffsq03LQ7jkELtoCX69Fy_lz_FuPh_1V_CtcmR9MDe_D28P0juM7zqKaQt13YWc5X8TFipKV_kifHLweACy8 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3NbtQwELagSBUXRPkNFDASN4iaxD-Jj2jpqvy0QohKvVm2Y5dKkK12s4feeAfeoo_VJ2HGTrZdCgekXBI7diZjx99kZj4T8oo7YYwLTe4luhmddbnloci5aJVRPHhmMXd4_0DuHfIPR-LoShZ_jHYfXZIppwFZmrp-57QNQ5J4s7PgJQCJHNYX9EFinM5NcouXJUP2_ImcXNLuFk1izcQfcqoqhrSZv7exvjRdw5vXwyb_8J3GJWl6l9wZsCR9m5S_RW747h7Z3B-85ffJ-RdvAE4vKABTCmZ-HuA8RcOe0VmgV3KvaDtfHtMfcYJjZ1iMufs0RYr7dqgMdjU96eisi2TXZ_Ti5y9qOjgStcnQKnXfZwu4B3ffnffxqqExdDEK5SlIPaZ40khw-4AcTne_TvbyYW-G3DEh-1wKJ11bFTVahMgBZ6Xk8F4dY7YxhpWW4Te4aUsZpGIBN7hxhrGalb5EzPWQbIDg_jGhPrLiBVHYpuK1NUoYHkRQqq2cDE5m5PWoFn2aKDh0dJ2zRiclalCijkrUVUa2R83pYTouNEMczBFcZeTlqhgmEnpHTOdnS6xTgy1WwfcpI4-SolfdAaqrSyWg8WZtCKwqIEn3ekl38i2SdeOeOQrs2oy8GUfL5XP9W4wn_1f9Bdn8_G6qP70_-PiU3K7ioMY4uG2y0c-X_hkAp94-j3PjN12JE38 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Reasons+for+non-feasibility+of+therapeutic+drug+monitoring+of+oral+targeted+therapies+in+oncology+-+an+analysis+of+the+closed+cohorts+of+a+multicentre+prospective+study&rft.jtitle=British+journal+of+cancer&rft.au=van+der+Kleij%2C+Maud+B+A&rft.au=Guchelaar%2C+Niels+A+D&rft.au=Meertens%2C+Marinda&rft.au=Westerdijk%2C+Kim&rft.date=2024-09-01&rft.issn=1532-1827&rft.eissn=1532-1827&rft.volume=131&rft.issue=5&rft.spage=843&rft_id=info:doi/10.1038%2Fs41416-024-02789-2&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-0920&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-0920&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-0920&client=summon |